Ovarian Cancer

• FDA label_change · 2025-01-03
  FDA Approved: DOXORUBICIN HYDROCHLORIDE — Supplemental Application (Zydus Lifesciences Limited)

  FDA approved a supplemental application for doxorubicin hydrochloride from Zydus Lifesciences Limited, updating the labeling for the product…

• EMA label_change · 2020-07-24
  Authorised uses of cancer medicine Yondelis unchanged following review of new data

  The EMA review concluded that the authorised uses of Yondelis (trabectedin) remain unchanged after evaluating new data.

• FDA label_change · 2018-04-06
  FDA Approved: RUBRACA — Supplemental Application (pharmaand GmbH)

  FDA approved a supplemental application for RUBRACA (rucaparib) submitted by pharmaand GmbH, expanding the labeling for ovarian cancer.